Literature DB >> 11386487

The association between intravenous haloperidol and prolonged QT interval.

K Hatta1, T Takahashi, H Nakamura, H Yamashiro, N Asukai, I Matsuzaki, Y Yonezawa.   

Abstract

Although intravenous haloperidol (HAL) is an effective medication that is often prescribed to treat agitation, several instances of torsade de pointes or prolonged QT interval have been reported. To investigate the association between intravenous HAL and QT prolongation and between intravenous HAL and ventricular tachyarrhythmia, a cross-sectional cohort study was performed that included measuring corrected QT intervals (QTc) on an emergency basis before intravenous HAL and continuously monitoring electrocardiographic (ECG) findings after intravenous HAL. During a 2-month period, 47 patients received intravenous injections to control psychotic disruptive behavior. According to clinical practice, patients were divided as follows. The FZ-alone group was treated with intravenous flunitrazepam (FZ), and the FZ-plus-HAL group received intravenous FZ followed by intravenous HAL. Although the difference in the mean QTc immediately after intravenous FZ between the two groups was not significant, the mean QTc after 8 hours in the FZ-plus-HAL group was longer than that in the FZ-alone group (p < 0.001). Four patients in the FZ-plus-HAL group had a QTc of more than 500 msec after 8 hours. The change in QTc during 8 hours significantly differed between the two groups (t = 2.64, p > 0.05). Furthermore, the change in QTc was moderately correlated with the dose of intravenous HAL, as evidenced by a coefficient of correlation of 0.48 (p < 0.001). However, ventricular tachyarrhythmia was not detected among 307 patients within a 1-year period, although the ECG was continuously monitored for at least 8 hours after intravenous HAL. The modest nature of QTc prolongation and the apparent absence of ventricular tachyarrhythmia under continuous ECG monitoring indicate that QTc prolongation associated with intravenous HAL is not necessarily dangerous. However, in an emergency situation, clinicians cannot exclude patients predisposed to torsade de pointes, such as those with inherited ion channel disorders. Therefore, clinicians should be aware of the association between intravenous HAL and QT prolongation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11386487     DOI: 10.1097/00004714-200106000-00002

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  15 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Wei Jiang; Heather Heinz; Amber Rayfield; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

5.  In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration.

Authors:  M T Blom; S Jansen; A de Jonghe; B C van Munster; A de Boer; S E de Rooij; H L Tan; N van der Velde
Journal:  J Nutr Health Aging       Date:  2015-05       Impact factor: 4.075

6.  Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.

Authors:  Andrew J Muzyk; Amber Rayfield; Jane Y Revollo; Heather Heinz; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

Review 7.  [Pharmacotherapy of psychiatric acute and emergency situations: General principles].

Authors:  T Messer; F-G Pajonk; M J Müller
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

8.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

9.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen; Yuki Takahashi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

10.  A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.

Authors:  Hideaki Katagiri; Shinji Fujikoshi; Takuya Suzuki; Kiyoshi Fujita; Naoya Sugiyama; Michihiro Takahashi; Juan-Carlos Gomez
Journal:  BMC Psychiatry       Date:  2013-01-11       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.